HRP20090505T1 - Homogemcitabini - Google Patents
Homogemcitabini Download PDFInfo
- Publication number
- HRP20090505T1 HRP20090505T1 HR20090505T HRP20090505T HRP20090505T1 HR P20090505 T1 HRP20090505 T1 HR P20090505T1 HR 20090505 T HR20090505 T HR 20090505T HR P20090505 T HRP20090505 T HR P20090505T HR P20090505 T1 HRP20090505 T1 HR P20090505T1
- Authority
- HR
- Croatia
- Prior art keywords
- general formula
- represents hydrogen
- group
- represent
- compound according
- Prior art date
Links
- 238000000034 method Methods 0.000 claims abstract 11
- 239000003814 drug Substances 0.000 claims abstract 5
- 238000004519 manufacturing process Methods 0.000 claims abstract 5
- 239000013543 active substance Substances 0.000 claims abstract 3
- 201000010099 disease Diseases 0.000 claims abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract 3
- 230000002062 proliferating effect Effects 0.000 claims abstract 3
- 150000001875 compounds Chemical class 0.000 claims 25
- 229910052739 hydrogen Inorganic materials 0.000 claims 23
- 239000001257 hydrogen Substances 0.000 claims 23
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 13
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims 10
- 125000006239 protecting group Chemical group 0.000 claims 9
- 125000000217 alkyl group Chemical group 0.000 claims 7
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims 7
- 125000004432 carbon atom Chemical group C* 0.000 claims 7
- 150000002431 hydrogen Chemical group 0.000 claims 7
- 239000000126 substance Substances 0.000 claims 7
- 238000003776 cleavage reaction Methods 0.000 claims 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 5
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims 5
- 230000007017 scission Effects 0.000 claims 5
- 229940079593 drug Drugs 0.000 claims 4
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 4
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- 230000003213 activating effect Effects 0.000 claims 3
- 125000000468 ketone group Chemical group 0.000 claims 3
- 238000002360 preparation method Methods 0.000 claims 3
- 206010005003 Bladder cancer Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims 2
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims 2
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 claims 2
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 2
- 229960005277 gemcitabine Drugs 0.000 claims 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims 2
- 125000003172 aldehyde group Chemical group 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 claims 1
- 229940104302 cytosine Drugs 0.000 claims 1
- CSJLBAMHHLJAAS-UHFFFAOYSA-N diethylaminosulfur trifluoride Substances CCN(CC)S(F)(F)F CSJLBAMHHLJAAS-UHFFFAOYSA-N 0.000 claims 1
- 239000012025 fluorinating agent Substances 0.000 claims 1
- 238000003682 fluorination reaction Methods 0.000 claims 1
- 150000004678 hydrides Chemical class 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- RXXXGJINTARBNA-UHFFFAOYSA-N n-ethyl-n-(trichloro-$l^{4}-sulfanyl)ethanamine Chemical compound CCN(CC)S(Cl)(Cl)Cl RXXXGJINTARBNA-UHFFFAOYSA-N 0.000 claims 1
- 238000005580 one pot reaction Methods 0.000 claims 1
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 229910000033 sodium borohydride Inorganic materials 0.000 claims 1
- 239000012279 sodium borohydride Substances 0.000 claims 1
- 239000000543 intermediate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/073—Pyrimidine radicals with 2-deoxyribosyl as the saccharide radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AT0122405A AT502221A1 (de) | 2005-07-20 | 2005-07-20 | Homogemcitabine, verfahren zu ihrer herstellung sowie deren verwendung |
| PCT/AT2006/000308 WO2007009147A2 (fr) | 2005-07-20 | 2006-07-20 | Homogemcitabines |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20090505T1 true HRP20090505T1 (hr) | 2009-10-31 |
Family
ID=37669151
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20090505T HRP20090505T1 (hr) | 2005-07-20 | 2009-09-23 | Homogemcitabini |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20080249119A1 (fr) |
| EP (1) | EP1904511B1 (fr) |
| KR (1) | KR20080043312A (fr) |
| CN (1) | CN101243101A (fr) |
| AT (2) | AT502221A1 (fr) |
| AU (1) | AU2006272424A1 (fr) |
| BR (1) | BRPI0614004A2 (fr) |
| CA (1) | CA2615356A1 (fr) |
| DE (1) | DE502006004194D1 (fr) |
| DK (1) | DK1904511T3 (fr) |
| ES (1) | ES2328855T3 (fr) |
| HR (1) | HRP20090505T1 (fr) |
| PL (1) | PL1904511T3 (fr) |
| PT (1) | PT1904511E (fr) |
| RU (1) | RU2008106480A (fr) |
| SI (1) | SI1904511T1 (fr) |
| WO (1) | WO2007009147A2 (fr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20110128947A (ko) * | 2009-03-20 | 2011-11-30 | 앨리오스 바이오파마 인크. | 치환된 뉴클레오시드 및 뉴클레오티드 유사체 |
| BR112015010941A2 (pt) | 2012-11-13 | 2017-07-11 | Boyen Therapeutics Inc | pró-fármacos de gemcitabina e suas utilizações |
| JP6505388B2 (ja) * | 2013-07-31 | 2019-04-24 | 株式会社半導体エネルギー研究所 | ジオキソラン誘導体、液晶組成物及び液晶表示装置 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4526988A (en) * | 1983-03-10 | 1985-07-02 | Eli Lilly And Company | Difluoro antivirals and intermediate therefor |
| US4965374A (en) * | 1987-08-28 | 1990-10-23 | Eli Lilly And Company | Process for and intermediates of 2',2'-difluoronucleosides |
| CZ123493A3 (en) * | 1992-06-22 | 1994-02-16 | Lilly Co Eli | Stereoselective anionic glycosylation process |
| MX9303713A (es) * | 1992-06-22 | 1994-05-31 | Lilly Co Eli | Proceso estereoselectivo para preparar un derivadoribofuranosilo enriquecido con alfa anomero. |
| US5401861A (en) * | 1992-06-22 | 1995-03-28 | Eli Lilly And Company | Low temperature process for preparing alpha-anomer enriched 2-deoxy-2,2-difluoro-D-ribofuranosyl sulfonates |
| US5256798A (en) * | 1992-06-22 | 1993-10-26 | Eli Lilly And Company | Process for preparing alpha-anomer enriched 2-deoxy-2,2-difluoro-D-ribofuranosyl sulfonates |
| US5256797A (en) * | 1992-06-22 | 1993-10-26 | Eli Lilly And Company | Process for separating 2-deoxy-2,2-difluoro-D-ribofuranosyl alkylsulfonate anomers |
| US5252756A (en) * | 1992-06-22 | 1993-10-12 | Eli Lilly And Company | Process for preparing beta-anomer enriched 2-deoxy-2,2-difluoro-D-ribofuranosyl-arylsulfonates |
| TW466112B (en) * | 1998-04-14 | 2001-12-01 | Lilly Co Eli | Novel use of 2'-deoxy-2',2'-difluorocytidine for immunosuppressive therapy and pharmaceutical composition comprising the same |
-
2005
- 2005-07-20 AT AT0122405A patent/AT502221A1/de not_active Application Discontinuation
-
2006
- 2006-07-20 KR KR1020087004014A patent/KR20080043312A/ko not_active Application Discontinuation
- 2006-07-20 AU AU2006272424A patent/AU2006272424A1/en not_active Abandoned
- 2006-07-20 ES ES06760795T patent/ES2328855T3/es active Active
- 2006-07-20 AT AT06760795T patent/ATE435868T1/de not_active IP Right Cessation
- 2006-07-20 DK DK06760795T patent/DK1904511T3/da active
- 2006-07-20 CA CA002615356A patent/CA2615356A1/fr not_active Abandoned
- 2006-07-20 RU RU2008106480/04A patent/RU2008106480A/ru not_active Application Discontinuation
- 2006-07-20 PL PL06760795T patent/PL1904511T3/pl unknown
- 2006-07-20 EP EP06760795A patent/EP1904511B1/fr active Active
- 2006-07-20 US US11/996,203 patent/US20080249119A1/en not_active Abandoned
- 2006-07-20 DE DE502006004194T patent/DE502006004194D1/de not_active Expired - Fee Related
- 2006-07-20 WO PCT/AT2006/000308 patent/WO2007009147A2/fr active Application Filing
- 2006-07-20 SI SI200630413T patent/SI1904511T1/sl unknown
- 2006-07-20 BR BRPI0614004-1A patent/BRPI0614004A2/pt not_active IP Right Cessation
- 2006-07-20 CN CNA2006800305003A patent/CN101243101A/zh active Pending
- 2006-07-20 PT PT06760795T patent/PT1904511E/pt unknown
-
2009
- 2009-09-23 HR HR20090505T patent/HRP20090505T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP1904511A2 (fr) | 2008-04-02 |
| RU2008106480A (ru) | 2009-08-27 |
| AT502221A1 (de) | 2007-02-15 |
| CN101243101A (zh) | 2008-08-13 |
| DK1904511T3 (da) | 2009-10-12 |
| WO2007009147A2 (fr) | 2007-01-25 |
| ATE435868T1 (de) | 2009-07-15 |
| CA2615356A1 (fr) | 2007-01-25 |
| SI1904511T1 (sl) | 2009-12-31 |
| WO2007009147A3 (fr) | 2007-05-24 |
| EP1904511B1 (fr) | 2009-07-08 |
| US20080249119A1 (en) | 2008-10-09 |
| ES2328855T3 (es) | 2009-11-18 |
| PL1904511T3 (pl) | 2009-12-31 |
| BRPI0614004A2 (pt) | 2011-03-01 |
| DE502006004194D1 (de) | 2009-08-20 |
| AU2006272424A1 (en) | 2007-01-25 |
| PT1904511E (pt) | 2009-10-14 |
| KR20080043312A (ko) | 2008-05-16 |
| AU2006272424A8 (en) | 2008-05-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7254738B2 (ja) | アレナウイルス科およびコロナウイルス科のウイルス感染を処置するための方法 | |
| AU2012223012C1 (en) | Phosphoramidate derivatives of 5 - fluoro - 2 ' - deoxyuridine for use in the treatment of cancer | |
| JP6220484B1 (ja) | フィロウイルス科ウイルス感染症を処置するための方法 | |
| CA2745523C (fr) | Nucleotides de type uracylcyclopropyle | |
| JP2018531227A6 (ja) | アレナウイルス科およびコロナウイルス科のウイルス感染を処置するための方法 | |
| TW201012814A (en) | Cyclopropyl polymerase inhibitors | |
| AU2020203055A1 (en) | Beta-D-2'-deoxy-2'alpha-fluoro-2'-beta-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment | |
| EP3539546A1 (fr) | Analogues phosphanate de composés inhibiteurs du vih | |
| LU100724B1 (en) | Beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-c-substituted-4'-fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection | |
| JP2014058567A (ja) | 新規な細胞増殖抑制性７−デアザプリンヌクレオシド | |
| BRPI0709124A2 (pt) | composto purina e métodos de uso dos mesmos | |
| MX2011011160A (es) | Nuevos nucleosidos de 7-desazapurina para usos terapeuticos. | |
| AU2016322375B2 (en) | Composition rich in single isomer NUC-1031 and preparation method and use thereof | |
| MX2007004735A (es) | Derivados de purina para usarse como agonista de receptores a-2a de adenosina. | |
| JP2008514581A (ja) | 生体還元により活性化されるプロドラッグ | |
| EP2986120B1 (fr) | Inhibiteurs de méthyltransférase pour le traitement du cancer | |
| Fries et al. | Synthesis and biological evaluation of 5-fluoro-2'-deoxyuridine phosphoramidate analogs | |
| HRP20090505T1 (hr) | Homogemcitabini | |
| US20130336883A1 (en) | Deoxycytidine kinase binding compounds | |
| Li et al. | Synthesis and biological evaluation of a novel β-D-2′-deoxy-2′-α-fluoro-2′-β-C-(fluoromethyl) uridine phosphoramidate prodrug for the treatment of hepatitis C virus infection | |
| WO2005058246A2 (fr) | Procede de preparation de thymidine radiomarquee | |
| CA3235405A1 (fr) | Developpement de nouveaux analogues de la clofarabine pour cancerotherapie |